Tolmar Drug Patent Portfolio
Tolmar owns 3 orange book drugs protected by 24 US patents Given below is the list of Tolmar's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11771841 | Systems and methods for mixing syringe valve assemblies | 22 Dec, 2041 | Active |
| US11931559 | Systems and methods for mixing syringe valve assemblies | 22 Dec, 2041 | Active |
| US11564933 | Methods of treating testosterone deficiency | 12 Apr, 2039 | Active |
| US8492369 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 20 Dec, 2030 | Active |
| US10543219 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 12 Apr, 2030 | Active |
| US10617696 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 12 Apr, 2030 | Active |
| US11179403 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 12 Apr, 2030 | Active |
| US11426416 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 12 Apr, 2030 | Active |
| US8778916 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | 12 Apr, 2030 | Active |
| US8241664 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | 29 Mar, 2029 | Active |
| US11331325 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | 06 Jan, 2027 | Active |
| US11179402 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | 14 Apr, 2026 | Active |
| US8470359 | Sustained release polymer | 15 Oct, 2023 | Expired |
| US8840916 | Sustained release polymer | 13 Nov, 2020 | Expired |
| US9539333 | Sustained release polymer | 13 Nov, 2020 | Expired |
| US9914802 | Sustained release polymer | 13 Nov, 2020 | Expired |
| US6626870 | Stoppering method to maintain sterility | 27 Mar, 2020 | Expired |
| US6565874 | Polymeric delivery formulations of leuprolide with improved efficacy | 28 Oct, 2018 | Expired |
| US6773714 | Polymeric delivery formulations of leuprolide with improved efficacy | 28 Oct, 2018 | Expired |
| US8486455 | Polymeric delivery formulations of leuprolide with improved efficacy | 28 Oct, 2018 | Expired |
| US9254307 | Polymeric delivery formulations of leuprolide with improved efficacy | 28 Oct, 2018 | Expired |
| US9283282 | Sustained release polymer | 28 Oct, 2018 | Expired |
| US5599552 | Biodegradable polymer composition | 04 Feb, 2014 | Expired |
| US6395293 | Biodegradable implant precursor | 28 Sep, 2013 | Expired |
Latest Legal Activities on Tolmar's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tolmar.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US11931559 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US11771841 |
|
Email Notification
Critical
| 24 Apr, 2024 | US11931559 |
|
Email Notification
Critical
| 24 Apr, 2024 | US11771841 |
|
Email Notification
Critical
| 24 Apr, 2024 | US11771841 |
|
Email Notification
Critical
| 24 Apr, 2024 | US11931559 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US11771841 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US11931559 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Mar, 2024 | US11931559 |
| Recordation of Patent eGrant | 19 Mar, 2024 | US11931559 |
| Mail Patent eGrant Notification | 19 Mar, 2024 | US11931559 |
| Patent eGrant Notification | 19 Mar, 2024 | US11931559 |
|
Email Notification
Critical
| 19 Mar, 2024 | US11931559 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Mar, 2024 | US11931559 |
| Mail Patent eGrant Notification | 19 Mar, 2024 | US11931559 |
Tolmar Drug Patents' Oppositions Filed in EPO
Tolmar drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 23, 2013, by Generics [Uk] Limited. This opposition was filed on patent number EP09012462A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15186752A | Apr, 2023 | Aera A/S | Granted and Under Opposition |
| EP09012462A | Oct, 2013 | Generics [UK] Limited | Revoked |
Tolmar's Family Patents
Tolmar drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 39.7% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Tolmar Drug List
Given below is the complete list of Tolmar's drugs and the patents protecting them.
1. Eligard Kit
Eligard Kit is protected by 14 patents, out of which 12 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11771841 | Systems and methods for mixing syringe valve assemblies |
22 Dec, 2041
(17 years from now)
| Active |
| US11931559 | Systems and methods for mixing syringe valve assemblies |
22 Dec, 2041
(17 years from now)
| Active |
| US8470359 | Sustained release polymer |
15 Oct, 2023
(1 year, 2 months ago)
| Expired |
| US8840916 | Sustained release polymer |
13 Nov, 2020
(4 years ago)
| Expired |
| US9539333 | Sustained release polymer |
13 Nov, 2020
(4 years ago)
| Expired |
| US9914802 | Sustained release polymer |
13 Nov, 2020
(4 years ago)
| Expired |
| US6626870 | Stoppering method to maintain sterility |
27 Mar, 2020
(4 years ago)
| Expired |
| US6565874 | Polymeric delivery formulations of leuprolide with improved efficacy |
28 Oct, 2018
(6 years ago)
| Expired |
| US6773714 | Polymeric delivery formulations of leuprolide with improved efficacy |
28 Oct, 2018
(6 years ago)
| Expired |
| US8486455 | Polymeric delivery formulations of leuprolide with improved efficacy |
28 Oct, 2018
(6 years ago)
| Expired |
| US9254307 | Polymeric delivery formulations of leuprolide with improved efficacy |
28 Oct, 2018
(6 years ago)
| Expired |
| US9283282 | Sustained release polymer |
28 Oct, 2018
(6 years ago)
| Expired |
| US5599552 | Biodegradable polymer composition |
04 Feb, 2014
(10 years ago)
| Expired |
| US6395293 | Biodegradable implant precursor |
28 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eligard Kit's drug page
2. Fensolvi Kit
Fensolvi Kit is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11771841 | Systems and methods for mixing syringe valve assemblies |
22 Dec, 2041
(17 years from now)
| Active |
| US11931559 | Systems and methods for mixing syringe valve assemblies |
22 Dec, 2041
(17 years from now)
| Active |
| US8470359 | Sustained release polymer |
15 Oct, 2023
(1 year, 2 months ago)
| Expired |
| US9539333 | Sustained release polymer |
13 Nov, 2020
(4 years ago)
| Expired |
| US9914802 | Sustained release polymer |
13 Nov, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fensolvi Kit's drug page
3. Jatenzo
Jatenzo is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11564933 | Methods of treating testosterone deficiency |
12 Apr, 2039
(14 years from now)
| Active |
| US8492369 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
20 Dec, 2030
(5 years from now)
| Active |
| US10543219 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
12 Apr, 2030
(5 years from now)
| Active |
| US10617696 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
12 Apr, 2030
(5 years from now)
| Active |
| US11179403 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
12 Apr, 2030
(5 years from now)
| Active |
| US11426416 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
12 Apr, 2030
(5 years from now)
| Active |
| US8778916 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
12 Apr, 2030
(5 years from now)
| Active |
| US8241664 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
29 Mar, 2029
(4 years from now)
| Active |
| US11331325 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
06 Jan, 2027
(2 years from now)
| Active |
| US11179402 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
14 Apr, 2026
(1 year, 3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jatenzo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List